SM
INDP icon

Sabby Management’s Indaptus Therapeutics INDP Stock Holding History

Sabby Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-335
Closed -$164K – 177
2021
Q1 		$164K Buy
335
+244
+268% +$128K 0.03% 140
2020
Q4 		$35K Buy
+91
New +$39.7K 0.01% 103
2017
Q3 		– Sell
-41
Closed -$528K – 189
2017
Q2 		$528K Sell
41
-189
-82% -$2.29M 0.03% 134
2017
Q1 		$2.65M Hold
230
– – 0.14% 75
2016
Q4 		$2.93M Buy
230
+8
+4% +$93.4K 0.17% 79
2016
Q3 		$2.9M Sell
222
-110
-33% -$1.37M 0.11% 101
2016
Q2 		$3.35M Buy
332
+13
+4% +$117K 0.17% 74
2016
Q1 		$2.95M Buy
319
+20
+7% +$186K 0.15% 67
2015
Q4 		$3.59M Buy
299
+25
+9% +$321K 0.2% 79
2015
Q3 		$3.44M Buy
+274
New +$3.6M 0.14% 112

Other funds holding INDP

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sabby Management's INDP Position: Q2 2021 in Review

Sabby Management sold out of Indaptus Therapeutics (INDP) in Q2 2021, closing a stake of 335 shares — an estimated $164K sold.

Sabby Management first reported a position in INDP in Q3 2015 and held it in 10 quarters. The position peaked at $3.59M in Q4 2015. 10 funds tracked by Wall St. Rank hold INDP as of Q2 2021.

  • Sabby Management reported no remaining Indaptus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sabby Management sold 335 Indaptus Therapeutics shares in Q2 2021, an estimated $164K.
  • Sabby Management first reported a position in Indaptus Therapeutics in Q3 2015 and held it in 10 quarters.
  • Sabby Management's Indaptus Therapeutics position peaked at $3.59M in Q4 2015.
  • 10 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2021.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.